Focus on Optimized Dosing of Ibrutinib Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Opportunities to Optimize Cancer Policies Panel Discussion

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Nov

Today In Oncology

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Opportunities to Optimize Cancer Policies Panel Discussion

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Impact of Concomitant Noncancer Medications on Outcomes in Breast Cancer

NCCN Guidelines to Be Integrated Into OpenEvidence Medical AI Platform

Adding an Investigational Monoclonal Antibody to Ibrutinib May Allow Patients With CLL to Discontinue Daily Treatment

FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma

Armando Giuliano Honored With 2025 William L. McGuire Memorial Lecture Award